Xenetic Biosciences Provides Update on Substantial Patent Grants and Allowances in U.S. and Worldwide
Xenetic Biosciences Partner Completes First Patient Cohort in Phase 2 Study with MyeloXen™ for Multiple Sclerosis
Xenetic Biosciences to Hold Business Update Conference Call September 23 at 6:00 a.m. Eastern Time
Xenetic Biosciences Announces Ongoing Safety and Efficacy Data From Phase 2 Trial of ErepoXen(R)
Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial of ErepoXen(R)
Xenetic Biosciences Announces Dosing of First Patient on Dialysis in Phase 2a Clinical Study of ErepoXen(R)
Xenetic Biosciences Strengthens Technology Patent Portfolio
Xenetic Biosciences to Present at the Third Annual Marcum MicroCap Conference
Xenetic Biosciences Announces First Quarter 2014 Financial Results and Business Update
